STOCK TITAN

Haoxi Health Technology Limited Receives Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Haoxi Health Technology (HAO) received a notification from Nasdaq on October 31, 2024, regarding non-compliance with the minimum bid price requirement. The company's stock failed to maintain the required $1.00 minimum bid price for 30 consecutive business days from September 19 to October 30, 2024. HAO has been granted 180 calendar days, until April 25, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. If unsuccessful, the company may face delisting, though it may be eligible for additional time. HAO is considering options including a potential reverse share split to meet requirements.

Haoxi Health Technology (HAO) ha ricevuto una notifica da Nasdaq il 31 ottobre 2024 riguardo alla non conformità con il requisito del prezzo minimo di offerta. L'azione della società non è riuscita a mantenere il prezzo minimo di offerta richiesto di $1.00 per 30 giorni lavorativi consecutivi dal 19 settembre al 30 ottobre 2024. A HAO è stato concesso un termine di 180 giorni di calendario, fino al 25 aprile 2025, per riacquistare la conformità mantenendo un prezzo di chiusura di almeno $1.00 per un minimo di 10 giorni lavorativi consecutivi. In caso di insuccesso, la società potrebbe affrontare una sospensione, anche se potrebbe essere idonea per ulteriore tempo. HAO sta valutando opzioni tra cui una possibile riduzione del capitale per soddisfare i requisiti.

Haoxi Health Technology (HAO) recibió una notificación de Nasdaq el 31 de octubre de 2024 sobre el incumplimiento del requisito de precio mínimo de oferta. Las acciones de la compañía no lograron mantener el precio mínimo requerido de $1.00 durante 30 días hábiles consecutivos desde el 19 de septiembre hasta el 30 de octubre de 2024. A HAO se le ha otorgado un plazo de 180 días calendario, hasta el 25 de abril de 2025, para recuperar la conformidad manteniendo un precio de oferta de cierre de al menos $1.00 durante un mínimo de 10 días hábiles consecutivos. Si no tiene éxito, la compañía podría enfrentar una exclusión de la lista, aunque podría ser elegible para tiempo adicional. HAO está considerando opciones, incluyendo una posible split inverso de acciones para cumplir con los requisitos.

하오시 헬스 테크놀로지 (HAO)는 2024년 10월 31일 나스닥으로부터 최소 입찰가 요구 사항을 준수하지 못했다는 통지를 받았습니다. 회사의 주가는 2024년 9월 19일부터 10월 30일까지 30일 연속으로 요구되는 $1.00의 최소 입찰가를 유지하지 못했습니다. HAO는 2025년 4월 25일까지 최소 10일 연속으로 $1.00 이상의 마감 입찰가를 유지하여 준수를 회복할 수 있도록 180일의 기간이 부여되었습니다. 실패할 경우, 회사는 상장 폐지의 위험에 처할 수 있지만 추가 시간이 주어질 수 있습니다. HAO는 요건을 충족하기 위해 역주식 분할을 포함한 옵션을 고려하고 있습니다.

Haoxi Health Technology (HAO) a reçu une notification de Nasdaq le 31 octobre 2024 concernant le non-respect de l'exigence du prix minimum d'offre. L'action de la société n'a pas réussi à maintenir le prix minimum d'offre requis de 1,00 $ pendant 30 jours ouvrables consécutifs, du 19 septembre au 30 octobre 2024. HAO a reçu un délai de 180 jours calendaires, jusqu'au 25 avril 2025, pour retrouver la conformité en maintenant un prix d'offre de clôture d'au moins 1,00 $ pendant un minimum de 10 jours ouvrables consécutifs. En cas d'échec, la société pourrait faire face à une radiation, bien qu'elle puisse être éligible à un délai supplémentaire. HAO envisage des options, y compris un éventuel regroupement d'actions pour répondre aux exigences.

Haoxi Health Technology (HAO) erhielt am 31. Oktober 2024 eine Mitteilung von Nasdaq über die Nichteinhaltung der Mindestgebotspreisanforderung. Die Aktie des Unternehmens konnte den erforderlichen Mindestgebotspreis von 1,00 $ nicht für 30 aufeinanderfolgende Geschäftstage vom 19. September bis zum 30. Oktober 2024 aufrechterhalten. HAO wurde eine Frist von 180 Kalendertagen bis zum 25. April 2025 eingeräumt, um die Einhaltung wiederherzustellen, indem ein Schlussgebotspreis von mindestens 1,00 $ für mindestens 10 aufeinanderfolgende Geschäftstage aufrechterhalten wird. Bei Nichterfüllung könnte das Unternehmen mit einer Delistung konfrontiert werden, könnte jedoch für zusätzliche Zeit berechtigt sein. HAO zieht Optionen in Betracht, darunter einen potenziellen Rücksplit der Aktien, um die Anforderungen zu erfüllen.

Positive
  • None.
Negative
  • Stock price falling below $1.00 minimum requirement
  • Risk of potential Nasdaq delisting if compliance not achieved by April 25, 2025
  • Possible reverse stock split implementation which could affect share value

Insights

This Nasdaq compliance issue raises significant concerns about HAO's market position. With a market cap of $9.5M and shares trading below $1, the company faces material delisting risks. The 180-day compliance window provides some breathing room, but the likely need for a reverse stock split could signal deeper fundamental issues. The small market cap and price decline suggest weak investor confidence and potential liquidity challenges. The company's position as a Chinese online marketing provider adds regulatory and market access complexity. While operational impact is currently minimal, the delisting risk could significantly affect institutional investment access and overall market confidence.

BEIJING, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced that the Company received a letter (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) on October 31, 2024, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq.

Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s Class A ordinary shares for the 30 consecutive business days from September 19, 2024 to October 30, 2024, the Company no longer meets the minimum bid price requirement.

The Notification Letter does not impact the Company's listing on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until April 25, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s Class A ordinary shares must have a closing bid price of at least US$1.00 for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by April 25, 2025, the Company may be eligible for additional time to regain compliance or may face delisting.

The Company’s business operations are not affected by the receipt of the Notification Letter. The Company intends to monitor the closing bid price of its Class A ordinary shares and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split of its outstanding Class A ordinary shares, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.

About Haoxi Health Technology Limited

Haoxi Health Technology Limited is an online marketing solution provider headquartered in Beijing, China, specializing in serving healthcare industry advertiser clients. The Company’s growth is driven by the rise of news feed ads and the rapid development of the healthcare sector. The Company offers one-stop online marketing solutions, especially in online short video marketing, helping advertisers acquire and retain customers on popular platforms in China, such as Toutiao, Douyin, WeChat, and Sina Weibo. The Company is dedicated to reducing costs, increasing efficiency, and providing easy online marketing solutions to advertisers. For more information, please visit: http://ir.haoximedia.com.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the “Risk Factors” section of the registration statement filed with the U. S. Securities and Exchange Commission (the “SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Investor Relations

WFS Investor Relations Inc.

Janice Wang, Managing Partner

Email: services@wealthfsllc.com

Phone: +86 13811768559

+1 628 283 9214 


FAQ

What is the deadline for HAO to regain Nasdaq compliance?

HAO has until April 25, 2025 to regain compliance with Nasdaq's minimum bid price requirement.

What is the minimum stock price HAO needs to maintain for Nasdaq compliance?

HAO needs to maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.

When did HAO receive the Nasdaq notification letter?

HAO received the Nasdaq notification letter on October 31, 2024.

What solutions is HAO considering to address the minimum bid price deficiency?

HAO is considering implementing options including a potential reverse share split of its outstanding Class A ordinary shares.

Haoxi Health Technology Limited

NASDAQ:HAO

HAO Rankings

HAO Latest News

HAO Stock Data

8.79M
18.97M
61.2%
0.29%
1.87%
Advertising Agencies
Communication Services
Link
United States of America
Beijing